CEO of US Bio Company Realizes Billions in Profit After Exercising Stock Options

United Therapeutics Corp (NASDAQ: UTHR) Chairman and CEO Dr. Martine Rothblatt disclosed that she exercised two batches of stock options—9,500 shares each—on May 7 and May 11, immediately selling all shares on the open market at roughly $570 per share. Each transaction generated about $5.5 million, for a combined total of approximately $11 million (around KRW 15 billion). These trades were executed under a Rule 10b5-1 trading plan adopted on November 7, 2025. Following the sales, Dr. Rothblatt still directly holds about 40,000 shares and retains several hundred thousand more indirectly through spousal and family trusts. In the same filing, CFO James Edgemon reported exercising 10,000 options on May 11 and selling them at around $570 each, yielding roughly $5 million (about KRW 7 billion) and leaving him with approximately 18,800 shares of directly held stock.

On May 6, United Therapeutics announced first-quarter 2026 revenue of $781.5 million, a 2% decline from the prior year period, while highlighting significant clinical data from its large Phase 3 studies of Tyvaso for pulmonary arterial hypertension and Ralinepag for idiopathic pulmonary fibrosis (sec.gov). In mid-May, Tyvaso’s TETON-1 trial results were published in The New England Journal of Medicine and presented at the 2026 American Thoracic Society International Conference. The company also received FDA clearance to initiate its UHeart xenogeneic heart transplant clinical trial—underscoring back-to-back clinical and regulatory achievements in respiratory disease and organ transplantation (ir.unither.com).

United Therapeutics, headquartered in Silver Spring, Maryland, and Research Triangle Park, North Carolina, is a biopharmaceutical company focused on severe cardiopulmonary diseases. Its leading products include Tyvaso and Remodulin for pulmonary arterial hypertension (ir.unither.com). Operating as a public benefit corporation, United Therapeutics is also investing in 3D bioprinting and xenotransplantation technologies, pursuing a medium- to long-term goal of alleviating organ shortages (reddit.com).